Alkem Labs Q4 FY26: Revenue up 15%, profit falls

What Alkem reported in Q4 FY26

Alkem Laboratories reported a mixed set of numbers for Q4 FY26, with steady momentum in revenue but a sharp fall in net profit. Consolidated revenue from operations rose 14.6% year-on-year to ₹3,603 crore (₹36,033 million). Consolidated net profit for the quarter declined to ₹236 crore, with reports in the data citing a YoY drop in the 22.7% to 25.11% range. The divergence between top-line growth and bottom-line performance was attributed in the provided notes to margin erosion and operational headwinds. One market snapshot also described the environment as including operational and regulatory pressure during the quarter.

The quarter’s print stood out because it came alongside strong growth in operating metrics, even as reported profit slipped. EBITDA for Q4 FY26 was stated to be up 32.2% YoY, and another note said EBITDA increased by ₹569 crore YoY. Profit before exceptional items and tax rose 40.74% YoY to ₹557.82 crore in Q4 FY26, as per the numbers provided. The mix of these indicators suggests the quarter included items and cost dynamics that affected reported profit after tax.

Top-line strength: demand capture across markets

The revenue outcome was positioned as a sign of demand capture across domestic and international businesses. A summary line in the input stated revenue expanded by ₹460 crore. Revenue from operations was reported at ₹3,600 crore in one place and ₹3,603 crore (₹3,603.32 crore) in another, reflecting rounding and source differences in the provided material.

On the domestic side, India sales were reported at ₹2,324.5 crore in Q4 FY26, growing 8.8% YoY. Another transcript-style segment cited India business growth as “around five and a half odd percent” and said the street expected early double-digit growth, while international performance was described as compensating for the slower India growth. Since both statements are present in the input, the practical takeaway is that the India trajectory was debated, while international performance was cited as supportive.

Bottom-line pressure: what dragged net profit

While the input does not provide a detailed cost bridge, it explicitly points to margin erosion and operational headwinds as the key drivers behind the profit fall. The same market snapshot also referenced regulatory pressure. A transcript-style segment cited “labor cost inflow outflow” as a reason profit was lower in the quarter. Separately, brokerage commentary in the input noted the company expects additional operational costs from developing newer growth drivers such as the CDMO and medical technology segments.

It is also important to separate operating performance from headline profit. The data states profit before exceptional items and tax jumped 40.74% YoY to ₹557.82 crore in Q4 FY26, while reported net profit fell to ₹236 crore. With no further line-item disclosure in the provided text, the article can only attribute the gap to the stated margin and operational factors, and to quarter-specific cost movements highlighted in the transcript.

FY26 full-year performance: profit up, record EBITDA

For the full year FY26, Alkem reported consolidated revenue from operations of ₹14,712.2 crore (₹147,123 million), up about 13% YoY. Full-year net profit was reported at ₹2,301 crore (₹2,301.80 crore), up about 6% YoY, with one note specifying 6.3% growth. The company said it achieved record annual EBITDA surpassing ₹3,000 crore in FY26.

Vikas Gupta, CEO of Alkem, stated the company recorded its highest-ever EBITDA in FY26 and described top-line growth as broad-based across domestic branded generics and international business. He also cited improving business mix, operating leverage and continued cost discipline as contributors to margin expansion in FY26. The company framed FY27 as starting from a “firm foundation,” supported by a pipeline for international markets and increasing contribution from chronic therapies.

Stock reaction and near-term market bias

The results were announced during market hours, and Alkem’s share price was reported as ending up about 1.3% to 1.36% at around ₹5,452 per share on the BSE. At the same time, the input also flagged that the earnings mix could cause volatility as the market digests a profit miss against revenue expectations.

A separate “Market Bias” label in the input explicitly stated “Bearish.” That framing likely reflects the sharp YoY decline in quarterly net profit even as revenue grew strongly, and the uncertainty around near-term cost pressures highlighted across the notes.

FY27 guidance: growth targets and margin range

Alkem’s outlook commentary in the provided content included a set of directional growth expectations by geography and a margin range for FY27. The company aims to grow 100-150 basis points above the market in India, with double-digit growth expected. The US business is guided to grow in high single digits in dollar terms, supported by new launches. Non-US international markets are projected to deliver strong double-digit growth.

On profitability, the company guided for FY27 margins of 20-21%, contingent on stabilization of geopolitical and cost pressures. Another guidance-related datapoint in the input came from brokerage commentary, which said the effective tax rate is expected to rise to 35-37% in FY27E versus an earlier estimate of 20%.

Product pipeline: US launches, Tolvaptan, Lidocaine and semaglutide

The company outlined a FY27 product pipeline in the US market with plans for seven to eight launches during the year. Two launches were specifically identified as expected around September-October in the second half of FY27: Tolvaptan and Lidocaine patches. Separately, the input mentioned a semaglutide launch planned for March 2026, and also described semaglutide as a notable new launch.

The pipeline details matter because they connect management’s growth commentary to identifiable products and timelines already communicated. However, the material provided does not quantify potential revenue contribution, so any impact should be read as strategic direction rather than a forecast.

Broker views and valuation references in the input

One brokerage note in the provided text said Alkem’s quarterly performance was better-than-expected, with revenue exceeding estimates by 6%, EBITDA by 9%, and PAT by 13%, attributed partly to lower-than-anticipated R&D expenditure. The same note said Motilal Oswal revised earnings estimates down by 2% for FY26 and 4% for FY27 to reflect expected additional operational costs linked to CDMO and medtech initiatives. Motilal Oswal valued Alkem at 28 times 12-month forward earnings and cited a target price of ₹5,560.

Separately, another note stated Nomura maintained a ‘Buy’ rating on Alkem Labs with a target price of ₹5,430. These references indicate that, within the input set, there is a mix of caution (estimate cuts and cost concerns) and continued coverage support (maintained targets and ratings).

Key numbers at a glance

Market impact: why the quarter matters

For investors, the immediate market issue is the mismatch between revenue growth and reported profit. A 14.6% jump in revenue alongside a net profit decline to ₹236 crore tends to shift focus to costs, mix, and the durability of margins. The market snapshot in the input explicitly flagged the risk of volatility because the market is weighing a profit miss against revenue expectations.

Operationally, the input frames FY26 as a year of margin expansion and record EBITDA, but Q4 as a quarter with specific pressures. That contrast can influence how investors interpret FY27 guidance, particularly the 20-21% margin range, the mention of geopolitical and cost pressures, and the expected rise in effective tax rate to 35-37% in FY27E.

Analysis: balancing FY26 strength with Q4 concerns

The provided information points to a company that ended FY26 with strong full-year growth, record EBITDA above ₹3,000 crore, and management confidence in chronic therapies and new launches. At the same time, Q4 FY26 showed that profitability can still be vulnerable to quarter-specific cost movements and operational headwinds, even when sales momentum is healthy.

The pipeline details, including seven to eight US launches and the expected timing of Tolvaptan and Lidocaine patches in September-October, provide specific milestones for FY27. Brokerage commentary also suggests that investments in CDMO and medtech could add to operational costs, which aligns with the broader theme of near-term profitability pressure despite longer-term expansion plans.

Conclusion

Alkem’s Q4 FY26 results delivered strong revenue growth to ₹3,603 crore but a sharp decline in reported net profit to ₹236 crore, keeping the focus on margins and costs. For FY26, the company reported higher revenue and profit, along with record EBITDA surpassing ₹3,000 crore. Looking ahead, the key confirmed signposts include FY27 margin guidance of 20-21%, plans for seven to eight US launches, and the expected September-October timing for Tolvaptan and Lidocaine patches.